Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colin Green

Showing results (51-60 of 108) with videos related to

Pageof 11
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 13, 2019
Assessing cost-effectiveness of early intervention in Alzheimer's disease: An open-source modeling frameworkColin Green, Ron Handels, Anders Gustavsson, et al.
Drugs & Aging|April 13, 2006
A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's diseaseJoanna Kirby, Colin Green, Emma Loveman, et al.
Lancet (London, England)|December 25, 2007
Medical ethical violations in GazaColin Green, Asad Khan, Ghada Karmi, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 7, 2009
Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinomaMartin Hoyle, Colin Green, Jo Thompson-Coon, et al.
BMC Public Health|December 28, 2011
The cost-effectiveness of exercise referral schemesNana K Anokye, Paul Trueman, Colin Green, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 7, 2009
Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinomaMartin Hoyle, Colin Green, Jo Thompson-Coon, et al.
Trials|December 17, 2016
Detailed statistical analysis plan for a cluster randomised controlled trial of the Healthy Lifestyles Programme (HeLP), a novel school-based intervention to prevent obesity in school childrenSiobhan Creanor, Jenny Lloyd, Melvyn Hillsdon, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 4, 2002
Interleukin 1 and chronic rejection: possible genetic links in human heart allograftsJoannis E Vamvakopoulos, Craig J Taylor, Colin Green, et al.
Journal of the Neurological Sciences|August 14, 2024
Literature review and meta-analysis of natalizumab therapy for the treatment of highly active relapsing remitting multiple sclerosis in the 'suboptimal therapy' patient populationMary Chappell, Alice Sanderson, Tarunya Arun, et al.
Biochemical Pharmacology|May 29, 2009
G-quadruplex compounds and cis-platin act synergistically to inhibit cancer cell growth in vitro and in vivoMekala Gunaratnam, Colin Green, João Bruno Moreira, et al.
Pageof 11

Showing results (51-60 of 108) with videos related to

Sort By:
Pageof 11
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 13, 2019
Assessing cost-effectiveness of early intervention in Alzheimer's disease: An open-source modeling frameworkColin Green, Ron Handels, Anders Gustavsson, et al.
Drugs & Aging|April 13, 2006
A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's diseaseJoanna Kirby, Colin Green, Emma Loveman, et al.
Lancet (London, England)|December 25, 2007
Medical ethical violations in GazaColin Green, Asad Khan, Ghada Karmi, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 7, 2009
Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinomaMartin Hoyle, Colin Green, Jo Thompson-Coon, et al.
BMC Public Health|December 28, 2011
The cost-effectiveness of exercise referral schemesNana K Anokye, Paul Trueman, Colin Green, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 7, 2009
Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinomaMartin Hoyle, Colin Green, Jo Thompson-Coon, et al.
Trials|December 17, 2016
Detailed statistical analysis plan for a cluster randomised controlled trial of the Healthy Lifestyles Programme (HeLP), a novel school-based intervention to prevent obesity in school childrenSiobhan Creanor, Jenny Lloyd, Melvyn Hillsdon, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 4, 2002
Interleukin 1 and chronic rejection: possible genetic links in human heart allograftsJoannis E Vamvakopoulos, Craig J Taylor, Colin Green, et al.
Journal of the Neurological Sciences|August 14, 2024
Literature review and meta-analysis of natalizumab therapy for the treatment of highly active relapsing remitting multiple sclerosis in the 'suboptimal therapy' patient populationMary Chappell, Alice Sanderson, Tarunya Arun, et al.
Biochemical Pharmacology|May 29, 2009
G-quadruplex compounds and cis-platin act synergistically to inhibit cancer cell growth in vitro and in vivoMekala Gunaratnam, Colin Green, João Bruno Moreira, et al.
Pageof 11